{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:28:48Z","timestamp":1780511328826,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The role of the complement system and its membrane-bound regulatory proteins (mCRPs) in the pathogenesis of cancer is still a debatable issue. The current study aimed to evaluate the role of the complement regulatory protein, the decay-accelerating factor (CD55), in the pathogenesis of acute leukemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>CD55 gene expression was assessed in the peripheral blood of 34 patients with acute myeloid leukemia (AML), 26 patients with acute lymphoblastic leukemia (ALL), and 30 healthy controls by qRT-PCR. Also, CD55 gene knockdown was performed in HSB-2 (ALL cell line) using customized short hairpin RNA (shRNA). Flowcytometric analysis was done to ensure successful transfection, and MTT assay was performed to evaluate the cell viability post-transfection and silencing of CD55.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There was a significant downregulation of CD55 in acute leukemia patients compared to the healthy controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) with RQ values of AML, and ALL patients were 0.2499\u2009\u00b1\u20090.07427 and 0.2581\u2009\u00b1\u20090.09467, respectively. The MTT assay showed a significantly reduced viability of HSB-2 cells following posttranscriptional silencing of CD55 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) by 78.6% as compared to the non-transfected or mock-transfected cells. In the presence of human serum, there was a significant reduction in cell viability by 66.3% as compared to non-transfected controls (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). Regarding the cells co-transfected with CD55 and CD46 silencing plasmids, cell viability was significantly decreased by 70.6% compared to non-transfected cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>CD55 was significantly downregulated in acute leukemia. However, its in vitro silencing showed significant reduction in cell viability, giving it a dual opposing role in cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00299-7","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:02:08Z","timestamp":1748300528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The decay-accelerating factor (CD55) in acute leukemia patients and its query implication in cancer pathogenesis"],"prefix":"10.1186","volume":"37","author":[{"given":"Hisham","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Abdellateif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perihan","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abo-Aisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"1","key":"299_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","volume":"343","author":"JV Sarma","year":"2011","unstructured":"Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011;343(1):227\u201335. https:\/\/doi.org\/10.1007\/s00441-010-1034-0.","journal-title":"Cell Tissue Res"},{"key":"299_CR2","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3389\/fimmu.2018.02203","volume":"9","author":"P Macor","year":"2018","unstructured":"Macor P, Capolla S, Tedesco F. Complement as a biological tool to control tumor growth. Front Immunol. 2018;9:2203. https:\/\/doi.org\/10.3389\/fimmu.2018.02203.","journal-title":"Front Immunol"},{"key":"299_CR3","first-page":"7995","volume":"63","author":"S Br\u00e4ndlein","year":"2003","unstructured":"Br\u00e4ndlein S, Pohle T, Ruoff N, Wozniak E, M\u00fcller-Hermelink H, Vollmers PH. Natural IgM antibodies and Immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res. 2003;63:7995.","journal-title":"Cancer Res"},{"key":"299_CR4","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1002\/ijc.30025","volume":"138","author":"SK Devarapu","year":"2016","unstructured":"Devarapu SK, Mamidi S, Ploger F, Dill O, Blixt O, Kirschfink M, et al. Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors. Int J Cancer. 2016;138:2963\u201373. https:\/\/doi.org\/10.1002\/ijc.30025.","journal-title":"Int J Cancer"},{"key":"299_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI90962","volume":"127","author":"V Afshar-Kharghan","year":"2017","unstructured":"Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127:780\u20139. https:\/\/doi.org\/10.1172\/JCI90962.","journal-title":"J Clin Invest"},{"issue":"1","key":"299_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","volume":"40","author":"EKS Wong","year":"2018","unstructured":"Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol. 2018;40(1):49\u201364. https:\/\/doi.org\/10.1007\/s00281-017-0663-8.","journal-title":"Semin Immunopathol"},{"issue":"8","key":"299_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1099\/jgv.0.000498","volume":"97","author":"US Rangaswamy","year":"2016","unstructured":"Rangaswamy US, Cotter CR, Cheng X, Jin H, Chen Z. CD55 is a key complement regulatory protein that counteracts complement-mediated inactivation of Newcastle Disease Virus. J Gen Virol. 2016;97(8):1765\u201370. https:\/\/doi.org\/10.1099\/jgv.0.000498.","journal-title":"J Gen Virol"},{"key":"299_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1089\/vim.2007.0061","volume":"20","author":"KL Cummings","year":"2007","unstructured":"Cummings KL, Waggoner SN, Tacke R, Hahn YS. Role of complement in immune regulation and its exploitation by virus. Viral Immunol. 2007;20:505\u201324.","journal-title":"Viral Immunol"},{"issue":"10","key":"299_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9(10):729\u201340. https:\/\/doi.org\/10.1038\/nri2620.","journal-title":"Nat Rev Immunol"},{"key":"299_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fimmu.2019.01074","volume":"10","author":"A Geller","year":"2019","unstructured":"Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol. 2019;10:1074. https:\/\/doi.org\/10.3389\/fimmu.2019.01074.","journal-title":"Front Immunol"},{"key":"299_CR11","doi-asserted-by":"publisher","first-page":"22023","DOI":"10.1074\/jbc.M702588200","volume":"282","author":"RJ Abbott","year":"2007","unstructured":"Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, et al. Structural and functional characterization of a novel T cell receptor co regulatory protein complex, CD97-CD55. J Biol Chem. 2007;282:22023\u201332. https:\/\/doi.org\/10.1074\/jbc.M702588200.","journal-title":"J Biol Chem"},{"key":"299_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/978-1-4419-7913-1_12","volume":"706","author":"I Spendlove","year":"2010","unstructured":"Spendlove I, Sutavani R. The role of CD97 in regulating adaptive T-cell responses. Adv Exp Med Biol. 2010;706:138\u201348. https:\/\/doi.org\/10.1007\/978-1-4419-7913-1_12.","journal-title":"Adv Exp Med Biol"},{"key":"299_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4049\/jimmunol.177.2.1070","volume":"177","author":"M Capasso","year":"2006","unstructured":"Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I. Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol. 2006;177:1070\u20137. https:\/\/doi.org\/10.4049\/jimmunol.177.2.1070.","journal-title":"J Immunol"},{"key":"299_CR14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.4049\/jimmunol.149.6.2055","volume":"149","author":"RW Finberg","year":"1992","unstructured":"Finberg RW, White W, Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol. 1992;149:2055\u201360.","journal-title":"J Immunol"},{"key":"299_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00262-003-0402-y","volume":"52","author":"LG Durrant","year":"2003","unstructured":"Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 2003;52:638\u201342. https:\/\/doi.org\/10.1007\/s00262-003-0402-y.","journal-title":"Cancer Immunol Immunother"},{"key":"299_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jgh.13055","volume":"31","author":"T Murao","year":"2016","unstructured":"Murao T, Shiotani A, Fujita Y, Yamanaka Y, Kamada T, Manabe N, et al. Overexpression of CD55 from Barrett\u2019s esophagus is associated with esophageal adenocarcinoma risk. J Gastroenterol Hepatol. 2016;31:99\u2013106. https:\/\/doi.org\/10.1111\/jgh.13055.","journal-title":"J Gastroenterol Hepatol"},{"key":"299_CR17","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-07-1844","volume":"14","author":"J Ikeda","year":"2008","unstructured":"Ikeda J, Morii E, Liu Y, Qiu Y, Nakamichi N, Jokoji R, et al. Prognostic significance of CD55 expression in breast cancer. Clin Cancer Res. 2008;14:4780\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1844.","journal-title":"Clin Cancer Res"},{"key":"299_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1593\/neo.05679","volume":"8","author":"RD Loberg","year":"2006","unstructured":"Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. Inhibition of decay accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia. 2006;8:69\u201378. https:\/\/doi.org\/10.1593\/neo.05679.","journal-title":"Neoplasia"},{"key":"299_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1631\/jzus.2005.B0913","volume":"6","author":"Y Liu","year":"2005","unstructured":"Liu Y, Chen L, Peng SY, Chen ZX, Hoang-Vu C. Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 2005;6:913\u20138. https:\/\/doi.org\/10.1631\/jzus.2005.B0913.","journal-title":"J Zhejiang Univ Sci B."},{"key":"299_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215935","volume":"551","author":"R Bharti","year":"2022","unstructured":"Bharti R, Dey G, Lin F, Lathia J, Reizes O. CD55 in cancer: Complementing functions in a non-canonical manner. Cancer Lett. 2022;551: 215935. https:\/\/doi.org\/10.1016\/j.canlet.2022.215935.","journal-title":"Cancer Lett"},{"issue":"1","key":"299_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jbmr.3861","volume":"35","author":"B Shin","year":"2020","unstructured":"Shin B, Won H, Adams DJ, Lee SK. CD55 Regulates Bone Mass in Mice by Modulating RANKL-Mediated Rac Signaling and Osteoclast Function. J Bone Miner Res. 2020;35(1):130\u201342. https:\/\/doi.org\/10.1002\/jbmr.3861.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"299_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1084\/jem.20170438","volume":"214","author":"C Saygin","year":"2017","unstructured":"Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med. 2017;214(9):2715\u201332. https:\/\/doi.org\/10.1084\/jem.20170438.","journal-title":"J Exp Med"},{"key":"299_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2004.047100","volume":"55","author":"D Wang","year":"2006","unstructured":"Wang D, Dubois RN. Prostaglandins and cancer Gut. 2006;55:115\u201322. https:\/\/doi.org\/10.1136\/gut.2004.047100.","journal-title":"Prostaglandins and cancer Gut"},{"key":"299_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"299_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107019","volume":"126","author":"R Nabil","year":"2023","unstructured":"Nabil R, Abdellateif MS, Gamal H, Hassan NM, Badawy RH, Ghareeb M, El Ashry MS. Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia. Leuk Res. 2023;126: 107019. https:\/\/doi.org\/10.1016\/j.leukres.2023.107019.","journal-title":"Leuk Res"},{"issue":"4","key":"299_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods."},{"issue":"6","key":"299_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00005-011-0146-x","volume":"59","author":"M Kolev","year":"2011","unstructured":"Kolev M, Towner L, Donev R. Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz). 2011;59(6):407\u201319. https:\/\/doi.org\/10.1007\/s00005-011-0146-x.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"6","key":"299_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.it.2009.04.002","volume":"30","author":"MM Markiewski","year":"2009","unstructured":"Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30(6):286\u201392. https:\/\/doi.org\/10.1016\/j.it.2009.04.002.","journal-title":"Trends Immunol"},{"issue":"16","key":"299_CR29","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1158\/0008-5472.CAN-09-1918","volume":"69","author":"MM Markiewski","year":"2009","unstructured":"Markiewski MM, Lambris JD. Unwelcome complement. Cancer Res. 2009;69(16):6367\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1918.","journal-title":"Cancer Res"},{"issue":"2","key":"299_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","volume":"21","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2004.07.017.","journal-title":"Immunity"},{"issue":"3","key":"299_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121\u20136. https:\/\/doi.org\/10.4103\/aam.aam_56_18.","journal-title":"Ann Afr Med"},{"issue":"2","key":"299_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","volume":"37","author":"MC Carroll","year":"2012","unstructured":"Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37(2):199\u2013207. https:\/\/doi.org\/10.1016\/j.immuni.2012.08.002.","journal-title":"Immunity"},{"issue":"1","key":"299_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"issue":"1","key":"299_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1034\/j.1600-0609.2000.80097.x","volume":"64","author":"D Guc","year":"2000","unstructured":"Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol. 2000;64(1):3\u20139. https:\/\/doi.org\/10.1034\/j.1600-0609.2000.80097.x.","journal-title":"Eur J Haematol"},{"issue":"5\u20136","key":"299_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/10428199409073780","volume":"12","author":"T Seya","year":"1994","unstructured":"Seya T, Matsumoto M, Hara T, Hatanaka M, Masaoka T, Akedo H. Distribution of C3-step regulatory proteins of the complement system, CD35 (CRI), CD46 (MCP), and CD5S (DAF), in hematological malignancies. Leuk Lymphoma. 1994;12(5\u20136):395\u2013400.","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"299_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0165-2478(91)90171-6","volume":"29","author":"H Fukuda","year":"1991","unstructured":"Fukuda H, Seya T, Hara T, Matsumoto M, Kinoshita T, Masaoka T. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin\u2019s lymphoma. Immunol Lett. 1991;29(3):205\u20139. https:\/\/doi.org\/10.1016\/0165-2478(91)90171-6.","journal-title":"Immunol Lett"},{"issue":"14","key":"299_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/atm.2016.06.26","volume":"4","author":"I Kourtzelis","year":"2016","unstructured":"Kourtzelis I, Rafail S. The dual role of complement in cancer and its implication in anti-tumor therapy. Ann Transl Med. 2016;4(14):265. https:\/\/doi.org\/10.21037\/atm.2016.06.26.","journal-title":"Ann Transl Med."},{"issue":"8","key":"299_CR38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2174\/156800910793357952","volume":"10","author":"N Geis","year":"2010","unstructured":"Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets. 2010;10(8):922\u201331. https:\/\/doi.org\/10.2174\/156800910793357952.","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"299_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1281411","volume":"58","author":"FC Loeff","year":"2017","unstructured":"Loeff FC, van Egmond HME, Nijmeijer BA, Falkenburg JHF, Halkes CJ, Jedema I. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors. Leuk Lymphoma. 2017;58(9):1\u201314. https:\/\/doi.org\/10.1080\/10428194.2017.1281411.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"299_CR40","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1158\/1078-0432.ccr-1073-03","volume":"10","author":"Z Madjd","year":"2004","unstructured":"Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res. 2004;10(8):2797\u2013803. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1073-03.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"299_CR41","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.3390\/ijms21228470","volume":"21","author":"KM Pflug","year":"2020","unstructured":"Pflug KM, Sitcheran R. Targeting NF-\u03baB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer. Int J Mol Sci. 2020;21(22):8470. https:\/\/doi.org\/10.3390\/ijms21228470.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00299-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:02:09Z","timestamp":1748300529000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00299-7","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Human Ethics Review Committee of the NCI (No. CP2402-303\u2013021), in accordance with the 2011 Declaration of Helsinki. Written informed consents were obtained from all patients as well as the control healthy subjects who participated in the study. Also, they provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from all patients as well as the control healthy subjects who participated in the study. Also, they provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}